Cocrystals: A Regulatory Rebirth
Publisher: Triclinic Labs, Inc
Access this content
Your content has been opened.
Cocrystals: A Regulatory Rebirth has been emailed to . Entered the wrong email?
Don't see the content in your inbox?
Make sure to check your spam and other messages folders.
Can't get to your email right now?
To complete your registration and access this content, enter the sign-in code sent to your email.
Please enter a valid verification code.
Code sent to:
Register to access this content
By accessing content on the Pharmaceutical Manufacturing Resource Directory you agree to our Terms of Service and Privacy Policy; and, you acknowledge that your information may be shared with the content publisher.
What is the impact of recent changes in FDA guidance on regulatory and intellectual property issues? The FDA reclassification of cocrystals as active pharmaceutical ingredients (APIs) has created exciting opportunities for the pharmaceutical industry. That reclassification means cocrystals can now be developed as if they were polymorphs, providing new avenues for dealing with poor API physical properties and extending intellectual property lifetimes. It is important to understand how the revised guideline impacts API development, regulatory submissions, and intellectual property protection. Those topics are discussed in this whitepaper. Also considered is the importance of identifying whether an API is a salt or a cocrystal, a critical classification from a regulatory point of view. In addition, a list of FDA-approved, marketed cocrystals is presented. Finally, recommendations for cocrystal screening, evaluation, formulation, and production at scale are given.
Similar content you might be interested in
